Aurinia Pharmaceuticals (AUPH) stock is soaring 7.40% in Thursday's trading session following the release of impressive second-quarter financial results and an upward revision of its full-year guidance. The biotech company, which focuses on developing and commercializing therapies for severe autoimmune diseases, reported earnings that significantly exceeded analyst expectations.

For the second quarter of 2025, Aurinia posted earnings per share of $0.16, beating the FactSet consensus estimate of $0.13 and showing a substantial increase from $0.01 per share in the same quarter last year. The company's total revenue for the quarter reached $70.0 million, up 22% year-over-year and surpassing analyst projections of $63.8 million. Net product sales of LUPKYNIS, Aurinia's FDA-approved oral therapy for lupus nephritis, grew to $66.6 million, marking a 21% increase from the previous year.

Adding to the positive sentiment, Aurinia raised its full-year 2025 guidance. The company now expects total revenue in the range of $260 million to $270 million, up from its previous forecast of $250 million to $260 million. This upward revision, coupled with the strong quarterly performance, has bolstered investor confidence in Aurinia's growth trajectory and the commercial success of its key product, LUPKYNIS. The robust financial results and optimistic outlook demonstrate Aurinia's strengthening position in the autoimmune disease treatment market, particularly in addressing lupus nephritis, a severe complication of Systematic Lupus Erythematosus (SLE).